The most valuable minutes in a Dutch general practice are often the ones spent typing after the patient has left. For clinicians, the administrative tail of a consultation can stretch on, chipping away at the time reserved for care and contributing to a well-documented burnout crisis. OurMind, an Amsterdam-based startup founded in 2024, is betting its generative AI platform can reclaim those minutes by automating clinical documentation, not as a generic transcriber, but as a system that learns the specific templates and workflows of each hospital or clinic it serves.
Its early traction suggests the approach is finding an audience. According to lead investor 4impact capital, the platform is already in use across more than 300 general practices and 14 hospitals in the Netherlands [4impact, June 2026]. This footprint provided the foundation for a €2.1 million (approximately $2.4 million) seed round closed in June 2026 [AIPressroom, June 2026].
A Surgeon's Second Act
The company's clinical credibility is anchored by co-founder Paul Koning, MD, a former orthopedic surgeon. His prior venture, Prisma Network, was acquired by the European healthtech giant Doctolib, giving him a track record of building and exiting a company in the same ecosystem [PERPLEXITY SONAR PRO BRIEF]. He is joined by co-founders Marco Ferraz, Fredrik Gustafsson, and Renan Sales Barros [AIPressroom, June 2026]. This blend of deep healthcare domain expertise and technical execution was a key factor for 4impact capital, which led the seed round with participation from a group of general practitioners and medical specialists [AIPressroom, June 2026].
The platform is built for the regulated, high-stakes environment of a clinical setting, with certifications including ISO 27001 and the Dutch healthcare-specific NEN 7510 standard [AI World, June 2026]. The platform also enforces a strict data hygiene policy: audio is deleted immediately after processing, and transcripts are automatically purged after 72 hours [AI World, June 2026].
The Hospital-Specific Wedge
OurMind's differentiation lies in its focus on integration and specificity. The core product, OurMind Notes, acts as an AI medical scribe, transcribing physician-patient conversations. The critical step comes next, where the AI formats that conversation into structured clinical documentation tailored to a hospital's or clinic's own electronic health record (EHR) templates [PERPLEXITY SONAR PRO BRIEF].
The company is also developing OurMind Assistant, a suite of custom AI tools designed for other daily administrative tasks. These can handle drafting referral letters, answering protocol questions, and generating summaries [OurMind]. The platform supports over 68 languages, and the company plans to introduce specialized templates for psychosocial and mental health consultations [OurMind].
Navigating a Crowded Field
The market for AI clinical documentation assistants is both validation and challenge. OurMind enters a space with well-funded, U.S.-based competitors like Abridge, Nuance's DAX Copilot, and Suki, alongside European peers. The competitive pressure is significant, but it also confirms a large, global demand. OurMind's initial wedge appears to be a focused, local-market strategy, building deep integrations within the Dutch healthcare system before expanding.
The risks for any early-stage company in this category are substantial. They include regulatory navigation, the technical complexity of EHR integration, and the commercial challenge of translating pilot usage into sustained, paying enterprise contracts.
The Road from Seed to Standard
The next twelve months will be about proving the commercial model. The seed capital provides runway to convert its initial 300-plus clinic footprint into a recurring revenue base and to pursue deeper integrations with major Dutch hospital systems. A key milestone to watch will be the announcement of a named, large hospital network as a formal customer.
For the clinicians using it, the value proposition is measured in saved hours and reduced cognitive load. By aiming to return time and focus to the patient encounter itself, the startup is betting that the most compelling case for its AI is not technological novelty, but humane utility.